Filing Flows › Pure Bioscience (PURE) › Q2 FY26
Pure Bioscience (PURE) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Mar 17, 2026
Pure Bioscience (PURE) reported revenue of $443K for the second quarter fiscal 2026 (Q2 FY26), +13% from a year earlier and -37% from the quarter before. Operating margin was -154.2%, net loss $785K (177.2% of revenue).
Pure Bioscience, Q2 FY26: revenue $443K (+13% year over year), operating margin -154.2%, net loss $785K, operating cash flow −$606K. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $443K | -37% | +13% |
| Operating profit | −$683K | — | — |
| Net earnings | −$785K | — | — |
| Operating cash flow | −$606K | — | — |
What changed
Revenue was $443K in Q2 FY26, up 13% year over year and down 37% from the previous quarter. PURE Hard Surface was the largest line at 97% of revenue. PURE Hard Surface added $45K year over year (up 12%), 87% of the total change.
Gross margin was 53.7%, down 4.3 points from Q2 FY25. Operating costs exceeded revenue by $683K, an operating margin of -154.2%. Operating expenses fell 3% while revenue rose 13%. The quarter ended with a net loss of $785K, wider than the previous quarter's $464K loss.
Operating cash flow was −$606K. Non-cash charges added back $58K of share-based compensation. Working capital and other items added $121K.
Questions
What was Pure Bioscience's revenue in the second quarter fiscal 2026?
Pure Bioscience (PURE) reported revenue of $443K for the second quarter fiscal 2026 (Q2 FY26), +13% from a year earlier and -37% from the quarter before.
Was Pure Bioscience profitable in the second quarter fiscal 2026?
Operating loss was $683K (-154.2% of revenue) and net loss $785K.
Source: Pure Bioscience 10-Q on SEC EDGAR.